2023 World Conference on Lung Cancer (Posters)-EP11.03. Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy

EP11.03. Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study compared real-world outcomes in patients with advanced non-small cell lung cancer (aNSCLC) receiving first-line (1L) immunotherapy alone or in combination with chemotherapy. The analysis used the EXPLORE-LC Korea database and included patients diagnosed with aNSCLC between January 2014 and December 2019. The study followed up with patients until March 2020 and divided them into two cohorts: those who received approved immunotherapy (n=133) and those who received immunotherapy with chemotherapy (n=57) as 1L treatment.<br /><br />The baseline characteristics of the patients showed significant differences between the two cohorts in terms of histology and PD-L1 expression. However, there was no statistically significant difference in real-world outcomes such as overall survival (rwOS), time to treatment discontinuation (rwTTD), and time to next treatment (rwTTNT) between the two treatment groups. The median rwOS for patients receiving immunotherapy alone was 14.40 months, while for those receiving immunotherapy with chemotherapy, it was 17.47 months. The median rwTTD was 2.37 months for immunotherapy alone and 4.00 months for immunotherapy with chemotherapy. The median rwTTNT was 4.17 months for immunotherapy alone and 5.73 months for immunotherapy with chemotherapy.<br /><br />The study highlights that real-world outcomes were not significantly different for patients receiving immunotherapy alone or immunotherapy with chemotherapy as first-line treatment for aNSCLC. However, the authors acknowledge the need for further investigation to increase the level of evidence and explore potential interactions with key prognostic factors. The findings provide valuable insights into treatment options for aNSCLC patients with high PD-L1 expression based on real-world data analysis.

Asset Subtitle

Sun Min Lim

Meta Tag

Speaker Sun Min Lim

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

advanced non-small cell lung cancer

aNSCLC

first-line treatment

immunotherapy

chemotherapy

EXPLORE-LC Korea database

real-world outcomes

overall survival

time to treatment discontinuation

time to next treatment